CSL LTD
ASX: CSL (CSL FPO [CSL])
Kemas kini terakhir: 19 jam lalu175.59
-1.97 (-1.11%)
| Penutupan Terdahulu | 177.56 |
| Jumlah Dagangan | 4,246,940 |
| Harga / Pendapatan (P/E Ke hadapan) | 19.49 |
| Harga / Jualan (P/S) | 3.82 |
| Harga / Buku (P/B) | 4.04 |
| Julat 52 Minggu | |
| Hasil Dividen (DY TTM) | 2.44% |
| Margin Keuntungan | 18.04% |
| Margin Operasi (TTM) | 32.68% |
| EPS Cair (TTM) | 8.34 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 5.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 58.23% |
| Nisbah Semasa (MRQ) | 1.86 |
| Aliran Tunai Operasi (OCF TTM) | 2.95 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.78 B |
| Pulangan Atas Aset (ROA TTM) | 6.69% |
| Pulangan Atas Ekuiti (ROE TTM) | 14.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | CSL FPO [CSL] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.06 |
|
CSL is one of the largest global biotech companies and has three main segments. CSL Behring uses either plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D record, and its product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and one-fourth in Europe. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Core |
| % Dimiliki oleh Orang Dalam | 0.30% |
| % Dimiliki oleh Institusi | 35.79% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |